Abstract Library

#4607 BH3-mimetic drugs elicit cell death of neuroendocrine tumours in preclinical models – An emerging therapeutic strategy for NETs

Introduction: There is an unmet clinical need to identify new, effective therapies for patients with neuroendocrine tumours (NETs). Analysis of single-cell expression data revealed that NETs express high levels of the Bcl2 family of antiapoptotic proteins. Therefore, we hypothesised that proapoptotic drugs, such as BH3-mimetics, can induce programmed cell death, i.e., apoptosis, of neuroendocrine cancer cells.

Conference:

Presenting Author: Michael I

Authors: Kulathunga N, Wang Z, Kale J, Lens A, Tsui H,

Keywords: neuroendocrine tumour, BH3-mimetics, Navitoclax, Cabozantinib, patient-derived organoids, apoptosis, 177Lu-Dotatate,

#4534 Development of new 3D in vitro models for pancreatic neuroendocrine tumours (PanNETs)

Introduction: Current PanNET in vitro models struggle to accurately replicate the tumour’s biology and microenvironment, limiting understanding of the mechanisms underlying PanNET behaviour and drugs response.

Conference:

Presenting Author:

Authors: Battistella A, Pinos R, Barbaglio F, Capurso G, Schiavo Lena M,

Keywords: Preclinical models, Pan NET, microenvironment, bioprinting, tumour slices, drug testing,

#4183 Establishment of novel patient-derived preclinical models for neuroendocrine tumors

Introduction: Neuroendocrine tumors (NETs) arise in different organs and are heterogeneous with limited treatment options. Preclinical models established from patient tumor specimens enable precision oncology by assessing the response to various drug treatments.

Conference:

Presenting Author: Michael I

Authors: Kulathunga N, Wang Z, Li B, Li Y, Tsui H,

Keywords: preclinical models, patient-derived organoids, patient-derived xenografts, drug screening,

#3931 Construction and comparison of non-functional pancreatic neuroendocrine tumor models

Introduction: Pancreatic neuroendocrine tumors (PNET) which account for more than 80% of pancreatic neuroendocrine neoplasm (pNEN) can be divided into functional and non-functional. The non-functional pancreatic neuroendocrine tumor (NF-pNET) without hormone-related clinical symptoms is frequently found by chance during physical examination or in large primaries and late stages of disease.

Conference:

Presenting Author: Wang Y

Authors: Wang Y, Ye Z, Lou X, Xu J, Zhou C,

Keywords: pancreatic neuroendocrine tumor, preclinical model, cell line, patient-derived organoid, patient-derived xenograft,

#3793 Decellularised pancreas explants as a novel 3D model for pancreatic neuroendocrine tumors (PNETs) biomarker discovery

Introduction: The lack of preclinical models of pancreatic neuroendocrine tumors (pNETs) challenges advancement in biomarker discovery. Culturing cancer cells in their native tissue enables the study of complex tumor cell-ECM interactions, products of which could be utilised as disease biomarkers.

Conference:

Presenting Author: Ney A

Authors: Ney A, Al-Akkad W, Sedlak E, Garcia-Sampedro A, Hall A,

Keywords: Disease model, Tumor microenvironment, Biomarker discovery, Pancreatic NET,